{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fernandez-Garcia D"],"funding":["Cancer Research UK","Pancreatic Cancer UK"],"pagination":["149"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6924016"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["Background
Breast cancer (BC) is the most common cancer in women, and despite the introduction of new screening programmes, therapies and monitoring technologies, there is still a need to develop more useful tests for monitoring treatment response and to inform clinical decision making. The purpose of this study was to compare circulating cell-free DNA (cfDNA) and circulating tumour cells (CTCs) with conventional breast cancer blood biomarkers (CA15-3 and alkaline phosphatase (AP)) as predictors of response to treatment and prognosis in patients with metastatic breast cancer (MBC).Methods
One hundred ninety-four female patients with radiologically confirmed MBC were recruited to the study. Total cfDNA levels were determined by qPCR and compared with CELLSEARCH® CTC counts a"],"journal":["Breast cancer research : BCR"],"pubmed_title":["Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer."],"pmcid":["PMC6924016"],"funding_grant_id":["18784","13462","20276","C14315/A13462","2013 RIF - Shaw","23464","C14315/A23464"],"pubmed_authors":["Hills A","Hastings RK","Gleason K","Toghill B","Guttery DS","Coombes RC","Shaw JA","Ogle O","Page K","Boydell AR","Rutherford M","Lim A","Ion C","Goddard KS","Fernandez-Garcia D"],"additional_accession":[]},"is_claimable":false,"name":"Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer.","description":"Background
Breast cancer (BC) is the most common cancer in women, and despite the introduction of new screening programmes, therapies and monitoring technologies, there is still a need to develop more useful tests for monitoring treatment response and to inform clinical decision making. The purpose of this study was to compare circulating cell-free DNA (cfDNA) and circulating tumour cells (CTCs) with conventional breast cancer blood biomarkers (CA15-3 and alkaline phosphatase (AP)) as predictors of response to treatment and prognosis in patients with metastatic breast cancer (MBC).Methods
One hundred ninety-four female patients with radiologically confirmed MBC were recruited to the study. Total cfDNA levels were determined by qPCR and compared with CELLSEARCH® CTC counts a","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Dec","modification":"2026-06-12T03:17:18.718Z","creation":"2020-05-22T01:04:32Z"},"accession":"S-EPMC6924016","cross_references":{"pubmed":["31856868"],"doi":["10.1186/s13058-019-1235-8"]}}